US 11,725,020 B2
Prodrugs of a CDK inhibitor for treating cancers
Jiasheng Lu, Shanghai (CN); Jiamin Gu, Suzhou (CN); Gang Chen, Suzhou (CN); Xiaolin Zhang, Suzhou (CN); Feng Zhou, Suzhou (CN); and Xianqi Kong, Dollard des-Ormeaux (CA)
Assigned to RISEN (SUZHOU) PHARMA TECH CO., LTD., Suzhou (CN); and SHANGHAI JUNSHl BIOSCIENCES CO., LTD., Shanghai (CN)
Filed by RISEN (SUZHOU) PHARMA TECH CO., LTD., Jiangsu (CN); and SHANGHAI JUNSHI BIOSCIENCES CO., LTD., Shanghai (CN)
Filed on Dec. 13, 2021, as Appl. No. 17/548,899.
Application 17/548,899 is a continuation of application No. 16/856,603, filed on Apr. 23, 2020, granted, now 11,225,497.
Claims priority of application No. 201910343182.5 (CN), filed on Apr. 26, 2019.
Prior Publication US 2022/0204541 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 9/6574 (2006.01); C07D 401/14 (2006.01); C07D 401/12 (2006.01); C07F 9/22 (2006.01); A61K 9/00 (2006.01)
CPC C07F 9/65744 (2013.01) [C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07F 9/222 (2013.01); A61K 9/0019 (2013.01); A61K 9/0053 (2013.01)] 20 Claims
 
1. A compound which is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or ester thereof.